Harvard College

Children's Medical Center Corporation

Other

Beth Israel Hospital Assoc.

Nuchem Pharmaceuticals Inc.

Ion Pharmaceuticals, Inc.

The Brigham and Women's Hospital, Inc.

Children's Hospital

Carlo Brugnara

Jose Alberto Halperin

Adel M Moussa

Ying-Duo Gao

Minghua Sun

Yesh P Sachdeva

Richard John Lombardy

John J Clifford

Eugene W Kelleher

Reem M Haidar

Heather N Taft

Emile M Bellott

Rudolf Fluckiger

Wayne I Lencer

Mark Froimowitz

Falguni M Kher

Emile M Bellot, Jr

Seth Alper

Seth L Alper

Michael H Zeldin

George M Whitesides

Thomas P Stossel

Charles R Mace

Yves Beuzard

Ashok A Kumar

Mark A Goldberg

Matthew Reiser Patton

Lucia De Francheschi

Frederick Galacteros

Venee Tubman

Margot S Kruskall

Jonathan W Hennek

Linda A Chambers

Harley Haynes

Caeul Lim

Yovany Moreno

Manoj T Duraisingh

Si-yi Ryan Lee

Gaetana D'Alesio-Spina

The present invention relates to the field of anti-malarials. In particular, the disclosure relates to methods for treating malaria in a subject by administering to said subject a potassium channel inhibitor. The disclosed potassium channel inhibitors provide wide bioavailability, long half-life, and good toxicity profiles while showing high potency for killing parasites which cause malaria. In certain exemplary embodiments, the potassium channel inhibitor is an inhibitor of calcium-activated potassium channels. In certain exemplary embodiments, the potassium channel inhibitor is an inhibitor of the Gardos channel.

Methods for treating malaria using potassium channel inhibitors

An aqueous multi-phase system for diagnosis of sickle cell disease is described, including two or more phase-separated phases including: a first aqueous phase including a first phase component and having a first density between about 1.025 g/cmand about 1.095 g/cm; and a second aqueous phase including a second phase component and having a second density between about 1.100 g/cmand about 1.140 g/cm; wherein the first density is lower than the second density; and each of the first and second phase components include at least one polymer.

Multiphase systems for diagnosis of sickle cell disease

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

A method and product for treating and preventing diarrhea and scours is provided. The method involves treating a subject who has diarrhea, or scours, or is at risk of getting diarrhea or scours with an aromatic compound of the invention. The products of the invention are a veterinary preparation of the aromatic compound of the invention and an anti-scours agent, and a pharmaceutical preparation of the aromatic compound of the invention and an anti-diarrheal agent.

Triaryl methane compounds and their use in the treatment of diarrhea and scours

The present invention provides a chemical class of active agents to be used as efficacious drugs in preventing erythrocyte dehydration, thus helping ameliorate the symptoms of certain hemoglobinopathies. The active agents include a class of compounds that can deliver to an erythrocyte in vivo a divalent cation. Increased intracellular concentrations of the divalent cation in the erythrocyte block K&mdash;Cl cotransport preventing dehydration of the erythrocyte, thus improving erythrocyte survival. These agents are to be administered by any preferred route of administration including oral, intravenous and parenteral routes. These agents may be co-administered with any other anti-hemoglobinopathic compounds. The methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in acute crisis clinical situations.

Use of divalent cations for inhibiting erythrocyte dehydration in vivo

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P, the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Triaryl methane compounds and analogues thereof useful for the treatment

Methods and products for treating diarrhea and scours: use of

The applicant has identified a particular class of imidazoles that inhibit angiogenesis. These imidazoles can be used to beneficially treat a variety of angiogenic conditions.

Treatments for diseases characterized by neovascularization

The Applicant has identified a particular class of imidazoles that inhibit nonprostate cancer cell proliferation. These imidazoles can be used to beneficially treat a variety of cancers. The imidazoles can be administered in a variety of formulations, including long-term sustained release implants and anti-cancer cocktails.

Cancer treatments

Growing community of inventors

Newton Highlands, MA, United States of America

Carlo Brugnara